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Rheumatic fever and rheumatic heart disease have been on the decline in the last 
century, but several episodes of resurgence in the United States and Europe, as well as 
continued high mortality in developing countries, reinforce the need for continued 
development of improved methods for detection of the causative agent,  Group A Strep 
pharyngitis.  Traditionally diagnosed via clinical and bacteriologic methods, newer 
molecular strategies to identify Group A Strep in patient samples have become available, 
but their acceptance for clinical testing has been thwarted by test complexity, expense, 
and lack of timeliness. With the advent of LAMP molecular technology, simpler 
molecular tests more appropriate for rapid, inexpensive diagnostic assays are becoming 
available. A comparison of one of these assays, illumigene® Group A Streptococcus 
DNA Amplification Assay, with traditional rapid antigen and culture testing from the 
perspective of sensitivity, specificity, accuracy, convenience and ease of use, time 
constraints, “real” value, process improvement, and cost was undertaken.  illumigene® 
outperformed combined antigen and culture testing in sensitivity, accuracy, and 
turnaround time.  Both methodologies were very similar for specificity and perceived test 
convenience.  In a data review from the perspective of diagnostic accuracy, illumigene® 
was 99.5% accurate compared to combined accuracy rate of  93.2% for antigen and 
culture testing, indicating that one case would have been misdiagnosed by illumigene®  
compared to 36 cases being misdiagnosed or treatment delayed using traditional testing 
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methods. Three different approaches to cost comparison yielded equivocal results that 
cannot be resolved without further real-world study, but illumigene® outperformed 
routine antigen and culture testing in two of three cost scenarios. Based on the data 
obtained in this study, illumigene® has proven to be a viable contender for inclusion in 
future algorithms for improved diagnosis of Group A Strep pharyngitis, and its use will 
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Rheumatic fever is a delayed autoimmune response to pharyngeal infection 
caused by Streptococcus pyogenes, commonly known as Group A Strep. A single 
untreated case of Group A Strep pharyngitis puts a person at risk for this lifelong, 
destructive, chronic disease. Major clinical symptoms of rheumatic fever can include 
heart murmur, joint swelling and tenderness, and chorea. Rheumatic fever, along with its 
chronic form rheumatic heart disease, has long been a public health problem worldwide, 
and while the number of cases in industrialized nations had been decreasing since the 
mid-20th Century, incidence has increased in less developed nations during the same 
period, especially in young adults.  In 1994, there were 12 million people worldwide 
afflicted with rheumatic fever and rheumatic heart disease. In 2000, there were an 
estimated 332,000 deaths in children and young adults globally (World Health 
Organization [WHO], 2004). Recurrent outbreaks of rheumatic fever in the United States 
that have occurred without warning or explanation (Veasy et al., 1987) have negated the 
maxim that rheumatic fever is present only in developing countries, and it is recognized 
that rheumatic fever remains an unconquered, increasingly serious global issue. 
Rheumatic fever and its chronic form rheumatic heart disease, arise specifically 
and exclusively from infection with Group A Strep pharyngitis. In the United States 
alone, 28–36 million throat cultures are obtained annually for sore throat. It is estimate 
that most children worldwide experience at least one episode of pharyngitis per year, 15–
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20% of which are caused by Streptococcus pyogenes, the most common cause of 
bacterial pharyngitis (Mahon, Lehman, & Manuselis, 2011). Surveys of healthy school 
children ages 6–10  years found antistreptolysin O titers, indicative of production of 
antibody to streptococcal infection, in 15–70%  of children, beta-hemolytic streptococcal 
carrier rates of 10–50% in asymptomatic school children, and in temperate climates, 50–
60% of streptococci isolated from asymptomatic children to belong to serogroup A 
(WHO, 2004). In the last 20 years, rates of Streptococcus pyogenes pharyngitis and 
asymptomatic carrier states have remained stable, but increased virulence and severity of 
infection have been documented (WHO, 2004; Veasy et al., 1987). These studies confirm 
the continued pathogenicity of this organism worldwide and underscore the need for 
further evaluation and control of the bacterium in human populations that clearly 
continue to undergo exposure to and infection with this microorganism. 
The primary symptoms associated with Group A Strep pharyngitis are tenderness 
and enlargement of cervical lymph nodes, tonsillar or pharyngeal exudate, pain on 
swallowing, and fever (Dos Santos & Berezin, 2005).   Similar symptoms, with the 
addition of cough, conjunctivitis and coryza, are more indicative of a viral entity. One of 
the confounders of diagnosis for Group A Strep pharyngitis is that presentation is quite 
variable depending on age group. For example, children younger than school age usually 
do not display the pharyngeal exudate or inflammation, and their symptoms are less 
acute. These children may not be medically evaluated because their parents may believe 
the child’s symptoms do not warrant treatment. Older children and adolescents are more 
likely to have classical symptoms as well as rash.  Symptoms of this bacterial infection 
are self-limiting and usually abate after about 5 days, even without antibiotic therapy.  If  
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a child has symptoms of Group A Strep pharyngitis and a throat swab is obtained, a 
negative result for Group A Strep traditionally prompts culture, which takes 24–48 hours 
for definitive identification. Antibiotics begun within 9 days of onset of symptoms of 
Group A Strep pharyngitis usually will prevent later kidney, cardiac, joint, or 
neurological sequelae (American Academy of Pediatrics, 2009). Conversely, receiving no 
antibiotic treatment, even though symptoms have abated, can result in rheumatic fever or 
other sequelae weeks after the initial throat infection. Factors to be considered in 
diagnosis of Group A Strep pharyngitis include age group of patient, country, season, 
socioeconomic conditions, exposure to someone with the infection, crowded living 
conditions, other environmental factors, genetic predisposition of host, quality and 
availability of health care, and education about the infection and health care 
recommendations, as well as infection level in the community.  
While a diagnosis of Group A Strep pharyngitis may appear straightforward, there 
is evidence that accurate clinical identification of this bacterial infection is more difficult 
than expected. In a study from 2005, children with sore throats were evaluated by 
physicians, who were asked, “Would you treat this child with antibiotics?” Physician 
recommendations were based entirely on clinical findings. Each case was subsequently 
evaluated with microbiological testing. Physicians in this study would have treated 47% 
of the Group A Strep-negative children and would not have treated 21% of the Group A  
Strep-positive cases. This study (Dos Santos & Berezin, 2005) lends credence to the 
judgment that a specific algorithm for diagnosis of Group A Strep pharyngitis, which 
includes both clinical and laboratory protocols, would improve patient outcomes.  
Nevertheless, diagnostic protocols continue to be quite variable (Facklam, 1976; Kellogg, 
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1990). A study reviewing 12 national guidelines for diagnosis of Group A Strep 
pharyngitis  (Chiappini et al., 2011) showed that in some European nations, sore throat is 
believed to be a common malady, “self limiting and benign,” that should be treated 
symptomatically only, and throat culture should be done only in very specific cases. In 
the United Kingdom, Scotland, Holland, and Belgium, rapid antigen detection tests from 
swabs are not recommended; rather, diagnosis of Group A Strep pharyngitis is made 
clinically and epidemiologically. In Canada, patients at risk for Group A Strep 
pharyngitis undergo throat culture but not rapid antigen testing. Even in the United 
States, there is disagreement among protocols, with guidelines differing based on which 
professional group is making the recommendations. For example, the American Society 
of Internal Medicine recommends culture only in children with appropriate Centor scores 
(Centor, Allison & Cohen, 2007; Tanz et al., 2009).  The American Heart Association 
and American Association of Pediatrics recommend evaluation of history, clinical 
findings and rapid antigen detection testing in all cases of suspected Group A Strep 
pharyngitis. If rapid antigen is negative, the sample should reflex to routine 24–48  hour 
microbiological culture for definitive diagnosis, especially in children. This is currently 
the gold standard for diagnosis of Streptococcus pyogenes pharyngitis. A direct antigen 
test can give results in minutes right in the health care provider’s office, but sensitivity of 
this test can average from 70% to 95%. As recently as 2008, significant discrepancy 
between rapid antigen detection testing and culture was documented, with sensitivity of 
rapid antigen at 70% and that of in-office culture 81% (Tanz et al., 2009). These data 
imply that a large number of patients with Group A Strep pharyngitis remain untreated. 
Sensitivity of rapid antigen detection testing improved with Centor scores in this review.  
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Newer technologies for diagnosis of Group A Strep pharyngitis have become available, 
such as fluorescence in situ hybridization and other nucleic acid probe methods, but these 
assays have proven no more sensitive than culture, and most remain costly and time-
consuming, involving much hands-on processing (Ding & Wang, 2011).  Rapid 
polymerase chain reaction (PCR) technology has a sensitivity equal to that of culture, 
with specificity of 98%, and could replace traditional culture, save for the cost of the 
technology (Slinger et al., 2011, Santos et al., 2003). Newer molecular assays employ 
some of the principles of PCR, but avoid some of its pitfalls. One such test is the 
illumigene® assay, a nucleic acid amplification procedure that is free from some of the 
time and temperature constraints of traditional PCR (Meridian Bioscience, 2012). 
The goal of this thesis is to compare three specific test methodologies for the 
diagnosis of Group A Strep pharyngitis with respect to sensitivity, specificity, accuracy, 
ease of use, convenience for operators, time constraints, real value, process improvement 
and cost, and to demonstrate data supportive of modification in current diagnostic 
algorithms. OSOM® Ultra Strep A Test (Sekisui Diagnostics, Lexington, MA), 
illumigene® Group A Streptococcus DNA Amplification Assay (Meridian Bioscience,  
Cincinnati, OH), and routine bacteriologic culture are the methods to be compared.  
OSOM® Ultra Strep A Test is a Clinical Laboratory Improvement Amendments 
(CLIA)-waived color immunochromatographic assay for the rapid qualitative detection of 
Group A Strep antigen directly from throat swabs. Viable and nonviable organisms can 
be detected within 7 minutes. The test strip, a lateral flow device, allows antibody to 
capture Group A Strep antigen if it is present and produce a visually detectable 
colorimetric change via capillary action and complex capture. See Appendix A.  
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The illumigene® Group A Streptococcus DNA Amplification Assay is a 
qualitative test for Group A Strep antigen obtained directly from throat swabs. This 
method employs a loop-mediated isothermal DNA amplification format (LAMP). See 
Appendix B. In the case of Group A Strep, this assay is designed to seek a segment of  
the Group A Strep SpeB gene. If this gene segment is identified, it is amplified, the 
detectable end-point of which is increased turbidity of the sample, a positive reaction. No 
change in turbidity implies that no Group A Strep DNA is present.  See Appendix C.  
A more specific diagnostic algorithm with emphasis on astute clinical diagnosis, 
rapid laboratory confirmation, and prompt and proper antibiotic treatment of Group A 
Strep is critical for control of rheumatic fever and other sequelae of Group A Strep 
infection. It is the hope of this writer that the observations herein will promote adoption 
of new diagnostic methods for Group A Strep pharyngitis, with the ultimate goal of 






Throat swabs from Primary Children’s Medical Center in Salt Lake City, Utah, 
were obtained per the American Academy of Pediatrics standard of care (American 
Academy of Pediatrics, 2009) and at physician discretion. Two throat swabs were 
obtained per person. The first swab was tested with the OSOM® Ultra Strep A Test. The 
second swab was used for routine culture per standard microbiology laboratory protocols 
(Intermountain Health Care [IHC] Laboratory Services, 1999; IHC Laboratory Services, 
2006). This second swab was then refrigerated and subsequently used for molecular 
testing on the illumigene® Group A Streptococcus Assay for detection of Group A Strep 
DNA.  Testing was conducted over a 62-day interval in the autumn of 2012.  All patient 
samples were submitted with a physician-directed order for Group A Strep testing, with 
the presumption that these patients had presented with signs and symptoms of Group A 
Strep pharyngitis (WHO, 2004). A total of 368 dual-swab samples were tested with the 
three methods. All swabs tested with the OSOM® Ultra Strep A Test for rapid antigen 
detection were processed in accordance with the procedural recommendations outlined in 
the package insert (Sekisui Diagnostics, 2012).  All swabs earmarked for testing with 
illumigene® were processed within 6 days of receipt in the microbiology laboratory and 
in accordance with the procedural instructions in the illumigene® Group A Streptococcus 
Assay package insert (Meridian Bioscience, 2012). Controls and system validations were 
also performed in accordance with procedural recommendations outlined in both package 
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inserts.   
Comparison of sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy of the different test methods was performed. In addition, 
factors relating to convenience of use and interpretation, cost, process improvement, and 
clinical value of the test protocols were evaluated. 
At our facility, the routine protocol for testing of throat swabs is to conduct 
OSOM® Ultra Strep A Test antigen screening within 1 hour of swab receipt, followed by 
routine 24–48 hour culture for clear-cut identification. In this pediatric population, 
negative antigen testing always reflexes to culture for definitive diagnosis. Since culture 
is still the traditional method for Group A Strep identification (Langlois & Andreae, 
2011), culture was the gold standard on initial testing in this study. Discrepant results 
between antigen testing, routine culture, and illumigene® were subsequently evaluated 
using an alternate nucleic acid amplification method targeting a nucleic acid sequence of 
the Streptococcus pyogenes SpeB gene that differed from the sequence sought in the 
illumigene® assay. This nucleic acid amplification procedure was used as our gold 
standard in the discrepancy testing portion of this study.  Since antigen testing and culture 
were both performed for each case as part of our facility’s protocol, data collected in this 
study were evaluated in one of two ways:  (1) either as three stand-alone tests being 
compared to each other or (2) OSOM® and culture as one test being compared to 
illumigene®.  Since the testing protocol for Group A Strep pharyngitis at our facility 
requires that rapid antigen detection test results be reported within 1 hour of swab receipt, 
a comparison was made between turnaround time for OSOM® (J.A. Daly, personal  
communication, January 31, 2013) and routine culture and illumigene® to see if 
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illumigene® could provide the 1-hour turnaround time required.  
The perceived convenience of the illumigene® procedure from the perspective of 
the test operators, comparing it to the routine rapid antigen/culture protocol, was 
assessed. Medical laboratory scientists familiar with both culture and illumigene® were 
questioned about seven convenience characteristics comparing both methods and ranked 
the protocols for the amount of training required, time to diagnosis, perceived complexity 
of the testing and equipment, number of steps required to complete the assay from start to 
finish, amount of hands-on time required to reach a final result, ease of interpretation for 
each test, and how often a test had to be repeated to obtain a valid result.  Operators 
ranked the protocols from least convenient (1+) to most convenient (4+).  See Appendix 
D. 
Hands-on versus hands-free time for test processing was evaluated for the three 
methods.  
Comparison of the cost for rapid antigen/routine culture testing versus that for the 
illumigene® molecular assay was performed as a part of this evaluation.  Several 
different cost perspectives were included to help clarify the real costs of these tests since 
actual test expenses and reimbursement are exceedingly variable and difficult to pinpoint. 
Raw data from our study data were evaluated with “cost” defined as time spent by  
clinical laboratory assistants and medical laboratory technologists per case (Bureau of 
Labor, 2013; Medical Laboratory Observer, 2013) plus material cost per case (J.A. Daly, 
personal communication, March, 2013).  A sampling of allowable reimbursement rates 
was also obtained to compare to the overall cost of the different test strategies (J.A. Daly, 
personal communication, January, 2014).  Meridian Bioscience financial projection data 
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were reviewed. In addition, information relating to actual cost of tests and allowable 
reimbursement amounts was obtained to compare to the costs we established for tests 
based on our data (James, 2014). 
The value of a laboratory assay, in the view of health care providers (A.J. 
Blaschke, personal communication, July 12, 2013), is its ability to provide a dependable 
answer about a patient sample within a reasonable length of time. When clinicians submit 
specimens for testing, they want the results to be accurate and trustworthy. Thus, a 
retrospective evaluation of the data accumulated in this study was performed to compare 
OSOM®, culture and illumigene® in a simulated laboratory setting as if all three 
methods were routinely employed on all throat swabs suspected of containing Group A 
Strep.  The goal was to compare the value, as defined above, of each of these tests either 
as stand-alone assays or in combination to see which would be the most beneficial to 








Using culture as the gold standard, initial sensitivity for OSOM® rapid antigen 
testing was 84.2% and specificity was 95.1%. Sensitivity for illumigene® was 97.6% and 
specificity 91.0%.  Positive predictive value (PPV) for OSOM® testing was 83.1% and 
for illumigene® 76.7%. Negative predictive value (NPV) for OSOM® testing was 95.4% 
and for illumigene® 99.2%. Overall accuracy for initial OSOM® testing was 92.7% 
while that for illumigene® was 92.9%.   See Table 1 for details. Positivity rate for the 
presence of Group A Strep was 22.6% (83/368) for OSOM®, 22.3% (82/368) for culture, 
and 28.3% (104/368) for illumigene® testing.  
Table 1 also illustrates results of discrepant resolution testing, which was 
performed using the alternate nucleic acid amplification method as our gold standard. 
Postdiscrepant resolution data showed sensitivity for OSOM® testing to be 73.1%, 
culture 76.9%, and illumigene® 99.0%. Specificity values postresolution were 97.3% for 
OSOM®, 99.2% for culture, and 99.6% for illumigene®.  PPV was 91.6% for OSOM®, 
97.6% for culture, and 99.0% for illumigene®, while NPV was 90.2%, 91.6%, and 
99.6%, respectively.  Overall accuracy for OSOM® testing was 90.5%, while that of 
culture was 92.9% and illumigene® 99.5%. 
As mentioned above, after discrepancy testing, 28.3% (104/368) of all cases 
submitted for testing were confirmed to be positive for Group A Strep. Of these, 












Total   Postdiscrepant 
Resolution 
Total 
Positive Negative  Positive  Negative  
Positive 69 14 83 76 7 83 
Negative 13 272 285 28 257 285 
Total 82 286 368 104 264 368 
       
Sensitivity 84.2%  69/82  73.1%  76/104  
Specificity 95.1% 272/285  97.3% 257/264  
PPV 83.1% 69/83  91.6% 76/84  
NPV 95.4% 272/285  90.2% 257/286  








Total  Postdiscrepant 
Resolution 
Total 
Positive Negative  Positive Negative  
Positive 80 24 104 103 1 104 
Negative 2 262 264 1 263 264 
Total 82 286 368 104 264 368 
       
Sensitivity 97.6% 80/82  99.0% 103/104  
Specificity 91.0% 262/286  99.6% 263/264  
PPV 76.9% 80/104  99.0% 103/104  
NPV 99.2% 262/264  99.6% 263/264  









Total  Postdiscrepant 
Resolution 
Total 
 Positive Negative  
Positive 82  82 80     2  82 
Negative  286 286       24 262 286 
Total 82 286 368 104 264 368 
       
 Sensitivity 76.9% 80/104  
Specificity 99.2% 262/264  
PPV 97.6% 80/82  
NPV 91.6% 262/286  




discrepant cases between routine culture and illumigene®, 23 culture negative cases were 
confirmed by PCR (and illumigene®) to contain Group A Strep DNA, reflecting that 
22% (23 of 104) of positive cases were missed by culture.  One culture positive case was 
misidentified and shown by PCR (and illumigene®) to lack Group A Strep DNA. Only 
two cases remained discrepant:  One illumigene® positive case was culture and PCR 
negative, representing a false positive rate of less than 0.4% for illumigene®. The other 
unresolved case was illumigene® negative and culture/PCR positive, representing a false 
negative rate of less than 1% for illumigene®. 
Our facility routinely uses OSOM® as its rapid test of choice to satisfy our 1-hour 
turnaround time requirement. The illumigene® assay is not currently in use by our 
facility on a routine basis, so swab receipt information was recorded during the study 
period in an effort to predict whether illumigene® could be performed within the desired 
1-hour time frame and without the need for sample batching. See Figure 1.  
As illustrated, distribution of swab receipt at our facility during the study period 
indicated that a mean of six throat swabs were submitted for Group A Strep testing in a  
 




given 24-hour period (range 1–12).  In our 62 days of testing, there were only three 
instances when more than two swabs were submitted within the same 30-minute time  
period. In each instance, a total of no more than three swabs arrived within the 30-minute 
interval. 
Medical laboratory scientists trained in both illumigene® and routine culture for 
Group A Strep were asked to compare the two protocols. See Table 2.  As far as training 
to learn the protocols, 25% of respondents ranked illumigene® as more convenient, 
while 75% saw no difference between illumigene® and culture.  All respondents ranked 
illumigene® as more convenient than culture with respect to time to diagnosis. Half of 
the respondents ranked culture as requiring fewer steps to diagnosis and being less 
complicated to perform, while 25% believed illumigene® had fewer steps and was less 
complicated; 25% saw no difference in this category.  Fifty percent of respondents ranked  
hands-on time for illumigene® to be more convenient than culture, 25% saw no 
difference, and 25% ranked culture as requiring less hands-on time.  All respondents 
ranked illumigene® as more convenient to interpret than culture. Fifty percent of 
 
Table 2:  Operator Perceptions of Convenience:  illumigene® Versus Culture 





Training time 25% --- 75% 
Time to diagnosis 100% --- --- 
Text complexity 25% 50% 25% 
Number of steps 
required 
25% 50% 25% 
Hands on time 
required 
50% 25% 25% 
Ease of 
interpretation 
100% --- --- 
Repeats required 25% 50% 25% 




respondents ranked culture as requiring fewer repeats to reach diagnosis, 25% ranked 
illumigene® more convenient in this regard, and 25% saw no difference. Overall, 
operators were evenly divided as to whether illumigene® or routine culture was more 
convenient. 
Once a swab was received in the clinical lab, an average of 2.25 minutes hands-on 
and 48.5 minutes hands-free time was required until results were available using the 
illumigene® assay.  In comparison, OSOM® rapid antigen screening test required an 
average of 2 minutes hands-on and 7 minutes hands-free time, but in this pediatric 
population reflexed to routine culture for confirmation.  Our culture protocol from receipt 
to identification based on the data set used in this study averaged 12 minutes of hands-on 
time.  Routine culture takes at least 24, and often 48 hours, for definitive diagnosis of 
Group A Strep, compared to the less than 1 hour receipt-to-result obtainable with both the 
OSOM® rapid antigen and illumigene® assays. See Table 3. 
To assess the value of the illumigene® assay as to “real world” worth from the 
perspective of health care providers, the raw data obtained in this study were reviewed 
retrospectively once the final test results were known, as if these samples had been 
routinely run as part of our usual clinical microbiology laboratory protocol. In our  
laboratory, throat swab samples suspected of containing Group A Strep are sent for 
immediate OSOM® rapid antigen screening. In this pediatric population, the screening  
test, if negative, reflexes to routine culture; however, a rapid screen that is positive for 
Group A Strep antigen allows the clinician to proceed with antibiotic treatment 
immediately, while a negative antigen screening test submitted for culture that at 24–48 
hours is positive for Group A Strep may delay more immediate treatment with antibiotics. 
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Table 3:  Hands-on and Hands-free Operator Time Associated with Test Methods Test	  protocol	   Hands-­‐on	  time	   Hands-­‐free	  time	   Time	  to	  Diagnosis	   Comments	  OSOM®	  Ultra	  Strep	  A	  Test	  (rapid	  antigen)	   5	  minutes	   7	  minutes	   Less	  than	  1	  hour	   Screen	  	  (A)	  Rapid	  antigen/primary	  culture	   8	  minutes	   24–48	  hours	   24–48	  hours	   Diagnostic	  (B)	  Rapid	  antigen,	  	  primary	  culture,	  subculture,	  PYR	  test	   25	  minutes	   24–48	  hours	   24–48	  hours	   Diagnostic	  (C)	  Rapid	  antigen,	  primary	  culture,	  subculture,	  PYR	  test,	  latex	   26	  minutes	   24–48	  hours	   24–48	  hours	   Diagnostic	  
Illumigene®	   2	  minutes	   49	  minutes	   Less	  than	  1	  hour	   Diagnostic	  
	  
 
Although the illumigene® assay is not yet routinely used for Group A Strep testing in 
our laboratory, this retrospective scenario was conducted with the postulation that either 
illumigene® would be used after antigen screening as the confirmatory assay or would 
replace both antigen screen and confirmatory culture.  See Table 4.  
Interestingly, results showed that if only the OSOM® Ultra Strep A Test for 
antigen screening had been performed on these swab samples, accuracy would have been 
90.2% with a 1-hour turnaround time.  If only routine culture had been performed on 
these samples, diagnostic accuracy would have been 92.9% with a 24–48 hour 
turnaround. If only illumigene® had been performed on these samples, diagnostic 
accuracy would have been 99.5% with a 1-hour turnaround time. Further, when antigen 
screening and culture were both used in this scenario, 15.4% (16/104) of cases positive 
for Group A Strep would have been missed entirely and likely left untreated, and 10.6% 
of positive cases (11/104) would have had treatment impacted with initiation of  
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Table 4:  Retrospective “What If” Scenario:  Routine Clinical 
                 Laboratory Testing of 368 Patients Symptomatic for GAS Pharyngitis 	   Test	  Protocol	   	  Accuracy	   Turn-­‐around	  Time	   Missed	  Positives	   	  Treatment	  Effect	  OSOM®	  only	  	   90.2%	  (333/368)	   Less	  than	  one	  hour	   28	   28	  GAS	  positive	  patients	  would	  	  not	  have	  received	  antibiotics;	  7	  unaffected	  patients	  would	  have	  	  been	  given	  antibiotics	  Routine	  culture	  only	  	   92.9%	  (342/368)	   24-­‐48	  hours	   23	   23	  GAS	  positive	  patients	  would	  	  not	  have	  received	  antibiotics;	  2	  unaffected	  patients	  would	  have	  	  been	  given	  antibiotics;	  antibio-­‐	  tic	  administration	  for	  GAS	  may	  	  have	  been	  delayed	  a	  day	  or	  two	  	  while	  awaiting	  culture	  results	  OSOM®	  and	  routine	  culture	  	  
93.2%	  (343/368)	   24-­‐48	  hours	   16	   16	  GAS	  positive	  patients	  would	  	  not	  have	  received	  antibiotics;	  	  11	  would	  have	  received	  antibio-­‐	  tics	  only	  after	  24-­‐48	  hours;	  9	  	  unaffected	  patients	  would	  have	  	  been	  given	  antibiotics	  
illumi-­‐gene®	  	   99.5%	   Less	  than	  one	  hour	   1	   1	  GAS	  positive	  patient	  would	  	  not	  have	  received	  antibiotics;	  	  1	  unaffected	  patient	  would	  	  have	  been	  given	  antibiotics	  
	  
 
antibiotics a day or two after initial visit because of the length of time required for 
definitive diagnosis by culture.   Finally, 3.4% (9/264) of culture-negative cases would 
have been misdiagnosed as having Group A Strep pharyngitis and would have been 
unnecessarily treated in the absence of the organism.   
Since OSOM® Ultra Strep A screening test and illumigene® diagnostic testing 
both support a turnaround time of less than 1 hour, it seems unreasonable to expect that 
they would both be used for one specimen in our clinical laboratory setting since the 
preponderance of our cases are from our emergency department or in-house clinics;  
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however, in the interest of this scenario,  which may be relevant to the outpatient setting, 
where immediate antigen testing may reflex to confirmatory testing in an outside 
laboratory, if they were both used, screening antigen testing would have been accurate in 
92.1% of these cases, with minimal treatment delay possible pending the illumigene® 
result, which would have been done more rapidly than culture, but would likely take 
more than 1 hour if the swab had to be transported from a distant outpatient setting for 
confirmatory testing.  
If illumigene® had been the diagnostic test of choice for all of these cases, 
without use of antigen screening or confirmatory culture, accuracy of the assay would 
have been, as mentioned, 99.5% with a turnaround time within 1 hour.  In all of our 
testing, only 0.5% of all cases run on illumigene® had to be rerun (2/368), thereby 
exceeding the 1-hour turnaround time, but the other 99.5% of tests produced a valid result 
within the 1-hour time frame required by this facility.  
“Cost” was evaluated from several different perspectives for purposes of 
clarifying this  less than transparent characteristic of health care. Initially, comparison of 
average labor and material costs for the two methods (OSOM® antigen/routine culture 
versus illumigene®) was performed on our raw data.  See Table 5. Primary culture 
procedures varied depending upon the rapid antigen result and the requirements to  
achieve isolated Group A Strep colonies. Data for the 368 cases were evaluated and each 
case assigned a cost value. See Table 6.  A total of  268 cases that were rapid antigen 
positive or negative and culture negative required the least testing and were the least 
expensive (A) at $8 per case (labor and materials).  Seventy cases that were antigen 
positive and culture positive had a midrange cost (B) of $25 per case.  Twelve rapid   
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Table 5.  Breakdown of Labor and Material Costs for Testing:  Individual Cases 	  
Labor Costs 
Clinical Laboratory Assistant (CLA) $24 per hour* 
Medical Laboratory Scientist (MLS) $46 per hour* 
 
Material Costs  








OSOM® $2 $2 (5 
minutes) 
 1 hour $4 Screen 
Primary 
plating 
$1 $1  (1 
minute) 



























$25 --- $2 (2 
minutes) 
55 minutes $27 Diagnostic 
* Hourly rate based on Medical Laboratory Observer and Bureau of Labor 3/12/13 
economic news release. 




Table 6:  Labor and Materials Costs:  Individual Cases 
Testing Protocol 






(A) Rapid antigen, primary culture  







(B) Rapid antigen,  primary culture, 
subculture, PYR test 







(C) Rapid antigen, primary culture, 
subculture, PYR test, latex 















Average material/labor cost per case overall for antigen and culture = $13 




antigen negative cases that were culture positive were most expensive (C) to process at 
$39 per case.   
      For our data, the average OSOM® rapid antigen/routine culture cost per case was 
$13. Mean case cost for illumigene® was $27. Allowable reimbursement rates from a 
sampling of insurance companies in our area revealed allowable reimbursement for rapid 
antigen/culture for Group A Strep pharyngitis to be around $18, while that for 
illumigene® was $34 (James, 2014).  According to the PCMC Cost Estimation 
Department, billing for OSOM® rapid antigen test/routine culture was $33 and for 
illumigene® $49 (J.A. Daly, personal communication, January, 2014).  See Table 7.  
Data were also obtained from Meridian Bioscience’s  Group A Strep Financial Analysis 
(Meridian Bioscience,  2014). See Table 8.  In this projection, test costs for all three 
methods were less than the corresponding costs on the Simplified Cost Calculation (Table 
7) using our study data, and the allowable reimbursement rate for culture was lower while 
that for illumigene® was higher. Interestingly, for one large local hospital corporation, 
the average cost in 2013 for an average OSOM® antigen test was actually $17 with 
corresponding allowable reimbursement maximum of $13 and average individual culture 
case cost of $10 with corresponding allowable reimbursement maximum of $5. The 
illumigene® Group A Strep DNA Assay was approved by the FDA for use beginning in 
2013, and no figures are yet available in this database for its actual cost, although the 
allowable reimbursement rate associated with this test is $34. See Table 9.    
 No capital expense is required for either illumigene® or OSOM® rapid antigen 
testing.  Culture requires use of an incubator. Molecular testing requires use of a hood.  
The incubator and hood, as well as minor incidental costs, such as pipette tips and gloves, 
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Table 8:  illumigene® Group A Strep Financial Analysis – Meridian Bioscience, Inc. 	  Test	  Method	   	  	  	  CPT	   Projected	  Cost	  (Meridian)	   Allowable	  Reimbursement	   	  	  	  	  Net	   Billing	  Amount	  OSOM®	  antigen	   	  87880	   	  $2	   	  no	  data	   	  no	  data	   	  	  $33	  Routine	  culture	   	  87081	   	  $0.50	   	  $4	   	  +$3.50	  




are shared with other assays run in our microbiology laboratory.  Regarding controls and 
repeat testing, illumigene® requires positive and negative controls be run on every new 
lot number, as does OSOM®. These costs are considered minimal and comparable for 
both tests, and calculations for their inclusion are not provided here. 
Taken as a whole, the characteristics of sensitivity, specificity, and accuracy, as 
well as convenience, speed, and economy of the assays were ranked from least desirable   
 (1+) to most desirable (3+). See Table 10.  OSOM® identified 73.1% of positive 
cases (28 of 104 positives missed) and culture identified 77% (23 of 104 positives 
missed) for an average sensitivity for the two tests combined of 75%. Sensitivity of 
illumigene® was 99%. OSOM®, culture and illumigene® had almost identical 
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Table 10:  Overall Comparison of OSOM®/Culture versus illumigene®  	  
Test Sensitivity Specificity Accuracy Economy Convenience Speed 
OSOM®/
Culture 
+ +++ + ++ ++      + 
Illumi-
gene® 
+++ +++ +++ ++ ++    +++ 
Overall Desirability of Test Protocols 
OSOM®/culture:  52% 
illumigene®:  91% 
  +++ more desirable          ++ no difference          + less desirable 
	  
 
specificity. Overall accuracy for illumigene® was over 99%, and that of OSOM®/culture 
was around 93%.  Average cost of OSOM®/culture testing was less than that of 
illumigene® on our raw data assessment, but was more expensive in the actual cost 
scenario than its corresponding reimbursement. Since actual cost for illumigene® for 
2013 is not available at this time,  comparison of actual cost with that of rapid 
antigen/culture could not be evaluated. Overall convenience as perceived by assay 
operators was the same for illumigene® and for OSOM®/culture. Hands-on versus 
hands-free time was better for illumigene® than OSOM®/culture. Time from receipt to 






The goal of this study was to compare traditional rapid antigen and culture 
methods for diagnosis of Group A Strep pharyngitis from throat swabs with the newly 
FDA approved illumigene® rapid molecular test for Group A Strep. As noted in the 
results of the study, illumigene® performed well on all of the characteristics evaluated. 
At first glance, with culture as our gold standard, illumigene® appeared to have the same 
overall accuracy as OSOM®. On closer examination of the results, however, 
illumigene® had a superior sensitivity (84.2% versus 97.6%), missing fewer than one 
Group A Strep case in 100, compared to OSOM®’s 16 missed cases per 100.  When our 
perspective shifted to use of the alternate nucleic acid method as gold standard, results 
were more dramatic. OSOM® had 73.1% sensitivity, culture 76.9%, and illumigene® 
99.0%, with respective accuracy of 90.5%, 92.9%, and 99.5%. Culture, traditionally the 
gold standard for diagnosis of Group A Strep pharyngitis, missed 23 cases of all Group A 
Strep-positive cases. The importance of improved sensitivity lies in the fact that one 
missed diagnosis of Group A Strep pharyngitis can result in sequelae such as rheumatic 
fever and its complications, as well as invasive forms of Group A Strep disease. A test 
that accurately diagnoses 99% of Group A Strep-positive cases compared to a method 
identifying only 76% is an appealing characteristic that favors this molecular method.  
A number of factors could explain the difference in accuracy across the three 
tests. Rapid OSOM® antigen testing historically has an accuracy rate against culture 
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varying from 94–99% (Veasy et al., 1987); however, under realistic conditions, using our 
standard culture protocol, OSOM® did not fare so well. This may be due to issues 
unrelated to the assay itself, such as improper sample collection or use of other than the 
recommended swab type. Discrepancies relative to culture could also be due to the fact 
that our culture protocol does not include use of Todd-Hewitt broth or SXT plates, two 
enhancement agents for the growth of the Group A Strep organism that have been used in 
validation studies for OSOM® testing; this may account for some of the false positives 
on OSOM® testing. The redeeming characteristics of OSOM® are that it is CLIA-
waived, relatively inexpensive, and does not require viable live organism to produce valid 
results. This screening test provides a result within less than 15 minutes with 73.5% 
accuracy. It is used as a point of care test and in a health care environment remote from a 
clinical laboratory will likely continue to be the first line of screening for Group A Strep 
pharyngitis. In fact, Meridian recognizes this fact and now sponsors a “Best of Both 
Worlds” campaign wherein for every two illumigene® kits purchased, Meridian provides 
three rapid antigen detection kits free of charge (Meridian Bioscience, 2014). 
It is difficult to define an average sensitivity and accuracy for culture itself 
because routine culture is not standardized. The literature supports an “average” 
sensitivity rate for bacteriologic culture of around 90–95% (Kellogg, 1990) with a 10% 
rate of error for swab collection variability. This level of sensitivity was not supported by 
our data, which showed sensitivity of culture to be 76.9%. Culture is fairly inexpensive,  
but requires live organism for successful subculturing, and even the most cursory 
diagnostic procedure cannot provide a result for at least 24–48 hours after swab receipt. 
Additionally, culture interpretation requires a medical laboratory scientist or  
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microbiologist. One characteristic of Group A Strep that may explain some missed 
diagnoses on culture is that 1% of Group A Strep does not produce beta hemolysis, one 
of the key identifiers on culture plates for diagnosis in the clinical laboratory (James & 
McFarland, 1971). Also, patients who have taken antibiotics may indeed be suffering 
from Group A Strep infection, but antibiotics render the organism nonviable very rapidly, 
and thus unculturable. Finally, quantity of Group A Strep in the sample affects its 
detectability, and obscuration by normal flora may limit visualization of minute quantities 
of Group A Strep on a culture plate.  Culture requires a minimum of 100,000 colony-
forming units of organism for visual detection, while illumigene® can detect as little as 
400  colony-forming units. (Meridian Bioscience, 2012).  
illumigene®, with its superior accuracy and sensitivity, does not require viable 
organism for testing, but does require processing by a medical laboratory scientist and 
takes about 50 minutes from swab receipt to diagnosis.  The illumigene® assay can be 
affected by zincum aceticum or zincum gluconicum-containing cold remedies such as 
Zicam, although there is no data clarifying for how long after use of Zicam the test result 
is affected. Patients with a history of recent use of these agents are not candidates for 
illumigene® testing until further research elucidates the duration of zincum interference. 
Anecdotally, however, the effects of zinc on the illumigene® assay are believed to  
resolve within an hour of administration (L. Reid, Personal Communication, April, 2014). 
Finally, illumigene® results could be impacted by the presence of an aberrant sequence 
of the  Streptococcus pyogenes SpeB gene, a specific segment of which it must detect to 
produce positive results. Either of these factors may be responsible for the single false 
negative case on illumigene® testing in our data. One downside of testing only on   
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nonviable organisms is that they cannot be subsequently cultured and saved for research 
purposes.  
A common complaint about some laboratory tests, both screening and diagnostic, 
is that they are too sensitive, and it is impossible to distinguish carrier status from 
infection status using these tests. Since swab testing occurs while sore throat symptoms 
are present, this is a difficulty that cannot be solved by the test itself.  The only true test 
of Group A Strep pharyngeal infection is the detection of antibody response to the 
infection, the production of which is the culprit that can cause damage in rheumatogenic 
cases. A patient is at risk for sequelae if not treated before antibody production begins, 
but waiting for the detection of antibody production to “prove” infection puts the patient 
at risk for these sequelae, so prevention of sequelae must take the form of astute clinical 
assessment while the patient is symptomatic, with patients suspicious for Group A Strep 
pharyngitis having their throats appropriately swabbed and the sample sent for 
confirmatory testing, followed by the administration of antibiotics in positive cases. Thus 
the algorithm for reliable diagnosis must include both discerning clinical evaluation and 
trustworthy laboratory testing that is rapid enough to obviate the need for empiric 
therapy.  Clinical guidelines for diagnosis vary depending upon many factors, but the  
Centor score algorithm, devised to differentiate clinically between viral and bacterial 
pharyngitis, was structured to minimize this clinical uncertainty, and  could be considered 
by clinicians as a useful algorithm for more accurate clinical diagnosis. See Appendix E.  
There is still the possibility that patients carrying detectable Group A Strep but suffering 
from viral pharyngitis may be erroneously treated with penicillin, but insightful clinical 
evaluation coupled with appropriate confirmatory testing should minimize this problem, 
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and this error pales in comparison to the 23 children suffering with Group A Strep 
pharyngitis that went undiagnosed in our data, children who were likely not treated and 
now carry the risk of falling victim to rheumatic fever or invasive Group A Strep 
infection.  
Molecular assays also have the reputation for being “too hands on” and time 
consuming and can be fraught with contamination problems. Some molecular assays 
require transfer of molecular material from one open tube to another, and then to another, 
with intervening, time-consuming steps that need to be done within a precise time frame. 
Many molecular procedures require that each step be conducted in a progressively less 
contamination-prone environment. These difficulties are minimized with the 
illumigene® assay. As illustrated in Appendix C,  illumigene® swabs are enclosed 
within a lysis tube. Drops from this closed lysis tube are expelled into a heat-treatment 
tube. Finally, this tube is opened, and small volumes are pipetted into a dual-chamber 
tube. One of these chambers is an internal control; the second is the sample reaction 
chamber. This tube arrangement minimizes the potential for contamination and also 
eliminates the need for extra controls being included on each run, as they are integral to  
each test device. Positive and negative controls are required only with each new kit or lot 
number. All steps of this procedure can be performed under the same hood. Processing 
external to the hood occurs either in the 95 oC heat block or the illumipro-10TM 
instrument. 
Since illumigene® is an isothermal reaction, it does not require as much time as  
traditional PCR methods, and hands-on processing time is less than 3 minutes.  A 
beneficial characteristic of this assay is that once components are placed on the 
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illumipro-10TM reader, the technologist can walk away. When the assay is finished, the  
instrument prints the result and shuts itself down without attention by the technologist.  
Although on our questionnaire for operators of illumigene® and culture, half of the 
respondents reported problems with invalid results, this observation was not borne out in  
our study. Only two of our 368 cases required repeat because of invalid results. Result  
options on the illumipro-10TM instrument are positive, negative or invalid, and are  
otherwise unequivocal.  A new set of samples can be started on the illumipro-10TM   
instrument every 36 minutes, so on-demand testing to meet 1-hour turnaround time  
is feasible within the constraints of our data set.  
One definite advantage of the illumigene® system is that at present each 
standalone illumipro-10™ instrument can accommodate testing for five different assays 
—Group A Strep, Group B Strep, Mycoplasma pneumoniae, Clostridium difficile, and 
Bordetella pertussis. Meridian is currently working on approval for more assays that will  
employ this instrument.  The illumipro-10™ instrument itself is flexible, also. The 
procedure is very similar for the five FDA-approved assays. Each illumipro-10TM 
instrument has two test drawers that will each accommodate five tests at a time, and a 
separate test can be run in each drawer simultaneously. With this instrument supporting 
five different assays in the clinical laboratory, its value will increase as test protocols 
change to include it.   
Molecular tests are historically expensive, so the issue of relative expense for all 
three test methods was a subject that required scrutiny in this study and unfortunately 
could not be unequivocally resolved.  On cursory analysis, material and labor costs for 
illumigene® are twice those for the combination of OSOM® and routine culture, but 
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even very careful labor and material cost evaluation for our data set was far from 
reflective of real world costs, at least for rapid antigen and culture testing.  Thus, it is 
important to consider not only costs of these assays but also the other relevant 
characteristics of these tests, as elucidated above, with particular mindfulness to the 
overall benefit to the welfare of our patients. Attempts to accurately predict test costs 
prospectively in the health care environment in which we now find ourselves is difficult 
at best, as is borne out by the contrast between allowable reimbursement and actual cost 
of the rapid antigen and culture tests costs from 2013 discussed above.  Looking at the 
stunning discrepancy between actual 2013 test costs that are roughly 150% of allowable 
reimbursement rates, one is compelled to contemplate how long a health care entity can 
continue to offer testing that it is essentially paying its patients to undergo. In the current  
health care environment, with actual and projected costs so difficult to ascertain, 
illumigene® is, at the very least, a competitive contender and deserves the opportunity to 
prove itself in the clinical setting.  
Each and every case of rheumatic fever is, by definition, preceded by a case of 
Group A Strep pharyngitis. Thus, a single undiagnosed case of Group A Strep pharyngitis 
can result in rheumatic fever with concomitant financial costs averaging more than 
$13,000 annually for medical care, lost parental wages, and absenteeism (Terreri et al., 
2001). One undiagnosed case of GAS pharyngitis can also result in invasive streptococcal 
infection, with an average cost in children of over $10,000 per case annually (Black & 
Shinefield, 2002); thus, a discussion of cost must include that to the patient if a case of 
Group A Strep pharyngitis is not accurately diagnosed.  Group A Strep pharyngitis 
treated immediately with intramuscular penicillin or oral penicillin, while sore throat is 
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still present, before the acute infection self-limits in about 5 days, has beneficial 
implications for the patient in terms of more rapid restoration of health, reduced 
infectivity, and reduced chance of developing sequelae. On the other hand, while Group 
A Strep remains exquisitely sensitive to penicillin, judicious use of this antibiotic is very 
important for maintaining the patient’s microbiome. Our question must be, “What is the 
best course of action for our patients?” Do we continue to use less expensive tests with 
reduced sensitivity and run the risk of subsequent infections, do we prescribe penicillin 
empirically, or do we look at all of the characteristics of the resources at our disposal and 
choose that which is the best for optimal patient outcome? 
For several decades, with advancements in therapies, procedures, and technology, 
medical costs have risen at an alarming rate, impacting both patients and health care 
systems. Several hospital corporations (Cosgrove et al., 2013; James & Savitz, 2011) 
have studied how to contain these costs and have implemented changes in their approach 
to health care management, with the direct goal being that of improving treatment and 
patient outcomes and indirectly to contain costs by shifting focus from provider to 
process variation. One such health care company has, through a feedback-loop protocol 
between evidence-based medicine algorithms, patients, and their providers, introduced a 
mechanism whereby protocols are introduced then modified by provider input relative to 
individual patient care. The providers supplying the input as “teachers” in this system, 
helping to modify and make more efficient the treatment algorithm, are also the 
“learners” in this system since the experience and input from a wide range of providers is 
gathered, collated, “fed back” into the system, and shared with all providers, and the 
protocol is modified accordingly. This approach is called “shared baselines,” and an 
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example of this feedback loop strategy was used to implement modification of and 
improvement in existing guidelines for labor induction by defining precisely via 
evidence-based indicators when induction was medically appropriate, collecting provider 
variations to this practice, collating variations and modifying guidelines, and deploying 
this information back throughout the entire system. The result, after several months of 
using this feedback loop, was to reduce the variation in physician practices, reduce the 
number of elective labor inductions from 28% of deliveries to less than 2%, and reduced 
health care costs in Utah by about $50 million annually. This technique was not 
implemented specifically to save money, but to directly improve efficiency and enhance 
patient care. A side-effect of the success of this change in treatment algorithm was the 
reduction in health care cost (James, 2011). Thus, perhaps inadvertently and 
unexpectedly, in the process of tweaking the existing treatment algorithm to improve 
patient outcome, cost was reduced. W. Edwards Deming, father of quality improvement, 
argued that most process changes that produce better physical outcomes also cause costs 
to fall (Deming, 1986), substantiated by the above example and by many others.  
As the trend continues toward the popularity of health care delivery groups, which 
are allotted a flat fee per month for patient care and are expected to use these funds to 
provide optimal care within these financial constraints, illumigene® is presented as a 
potential participant in new algorithms aimed at improvement in overall patient health 
and well being. All of the characteristics of illumigene® described in this text portend  
improvement of patient care and outcomes, and if Deming’s adage holds true, inadver-
tently and perhaps unexpectedly, the beneficial side-effect of reduced overall  health care 






It is clear from the above data that the illumigene® Assay for Group A Strep 
pharyngitis is both dependable and timely, fulfilling the value criteria for clinicians.   
After resolution of discrepant results in our study, illumigene® was proven to be a 
remarkably sensitive and specific assay, more accurate than either traditional method of 
testing, alone or combined.  Illumigene® performed very well in all aspects evaluated in 
this study and deserves the opportunity to prove itself as a valuable addition to the 
repertoire of the clinical laboratory. If given this opportunity, illumigene® will 
undoubtedly become a key player in efficient, cost-effective improvement in the 
diagnosis, treatment, and outcome of our patients afflicted with Group A Strep 










OSOM® ULTRA STREP A TEST  
 
 
Figure A.1. The OSOM® Ultra Strep A Test is a CLIA-waived color immunochromato-
graphic assay for the rapid qualitative detection of Group A Strep antigen directly from 
throat swabs. Viable and nonviable organisms can be detected within 7 minutes. The 
throat swab is subjected to chemical extraction of carbohydrate antigen specific to Group 
A Strep. The test strip, a lateral flow device coated with antibody-labeled color particles 
in two locations, is then placed in the extraction solution. Liquid migrates up the test 
strip. If Group A Strep carbohydrate antigen is present, it complexes with the labeled 
antibody impregnated in the strip (and eluted by the liquid). These complexes will bind 
the anti-Group A Strep capture antibody and a blue “positive” line will be visible. An 
internal control will also be visible when nonspecific antigen in the sample binds the 
nonspecific antibody impregnated in another section of the strip. This red line confirms 
the validity of the test.  The illustrated procedure depicts the following: (1) Obtain 
refrigerated reagent kit.  Bring reagents to room temperature. (2) Dispense 6 drops of 
reagent into test tube. (3) Agitate patient throat swab in reagent tube vigorously, and 
allow it to rest in tube for 2 minutes  (4) Remove swab from reagent tube and insert 
lateral flow device into reagent/patient sample tube. (5) Incubate at room temperature for 
6 minutes. (6) Remove lateral flow device from reagent/patient sample tube and read 
results. 
®
Ultra Strep A Test
Rev. 3098-1, 12/12
4 65321

















Figure B.1.  In this isothermal nucleic acid amplification method, several primers and a 
strand-displacement polymerase initiate the  amplification process, and are augmented by 
loop primers which enhance the rapidity and abundance of amplification, the result of 
which is magnesium pyrophosphate,  a compound causing turbidity to the reaction 
components. Detection of this turbidity implies the presence of Group A Strep DNA in 
the reaction chamber.  
LAMP Process
 1.  Solution temperature at 60º–65º C
 7. This strand forms a “stem loop” at the 5’ end due to 
  complementary F1 and F1c regions
Target DNA
 2. Forward Initiating Primer (FIP) anneals to 
  Target Sequence
 3. DNA Polymerase initiates synthesis that displaces 
  single strand template DNA
 4. Through polymerase activity, a strand complementary 
  to the DNA template is formed
 5. The F3 Primer anneals to the F3c Region
 9.  The B3 Primer anneals to the B3c target
 11. DNA reverts from a Loop structure to a linear structure
 12. The BIP linked complementary strand is displaced as 
  a single strand
 13. This strand forms stem-loops at either end due to the 
  activity of the dual complementary primers
 14. This is the starting structure for LAMP Cycling
(Continued on next page)
 6. DNA Polymerase initiates synthesis and the FIP-linked
  complementary strand is replaced
 8. The BIP anneals to the 3’ end of the “stem loop” strand
 10. From the 3’ end, polymerase synthesizes a 












15. LAMP Cycling. A dumbbell-like DNA structure is quickly   
 converted into a stem-loop DNA by self-primed DNA synthesis. 
 FIP anneals to the single stranded region in the stem-loop DNA  
 and primes strand displacement DNA synthesis, releasing the  
 previously synthesized strand. This released single strand forms  
 a stem-loop structure at the 3’ end because of complementary  
 B1c and B1 regions.
 Then, starting from the 3’ end of the B1 region, DNA synthesis  
 starts using self-structure as a template, and releases   
 FIP-linked complementary strand (STEP 2).
 The released single strand then forms a dumbbell-like structure  
 as both ends have complementary F1–F1c and B1c–B1   
 regions, respectively (STEP 4).
This structure is the ‘turn over’ structure of the structure formed in 
STEP 1. Similar to the STEPS 1 THROUGH 4, structure in STEP 4 
leads to self-primed DNA synthesis starting from the 3’ end of the 
B1 region.
Furthermore, BIP anneals to the B2c region and primes strand 
displacement DNA synthesis, releasing the B1-primed DNA strand. 
Accordingly, similar structures to STEPS 2 AND 3 as well as the 
same structure as STEP 1 are produced. With the structure 
produced in STEP 3, the BIP anneals to the single strand B2c 
region, and DNA synthesis continues by displacing double stranded 
DNA sequence. As a result of this process, various sized structures 
consisting of alternately inverted repeats of the target sequence on 
the same strand are formed.
For more information, contact an illumigene™ specialist at 1-888-763-6769 or visit us on the web at www.meridianbioscience.com. 







ILLUMIGENE® GROUP A STREPTOCOCCUS DNA AMPLIFICATION ASSAY 
 
 
Figure C.1. The illumigene® Group A Streptococcus DNA Amplification Assay is a 
qualitative test for Group A Strep antigen from throat swabs.  This loop-mediated 
isothermal DNA amplification technology (LAMP) uses specific primers to target a 
highly conserved 206-base-pair region of the Streptococcus pyogenes genome residing in 
the pyrogenic exotoxin B (SpeB) gene. Patient swab is inserted into a lysis solution that 
contains formalin-treated Escherichia coli containing Staphylococcus aureus DNA. Some 
of this solution is transferred into a heat-treatment dilution tube and incubated at 95oC for 
10 minutes. The test device has one test chamber containing Group A Strep-specific 
primers and one control chamber containing Staphylococcus aureus-specific primers. 
This control chamber functions as an internal control validating the test result by 
monitoring amplification inhibition, assay reagent performance and sample processing 
effectiveness. Control Staphylococcus aureus must be amplified and detected to have the 
test considered valid. Detection is not via the amplification itself but a by-product of the 
reaction, magnesium pyrophosphate, which is a white precipitate that produces a turbidity 
to the reaction solution. Change in sample absorbance resulting from precipitation of 
magnesium pyrophosphate indicates the presence of Group A Strep and is reported as 
positive. Lack of detectable change in absorbance is reported as negative. The illustrated 
procedure depicts the following: (1) Obtain patient swab; bring reagent kit to room 
temperature. (2) Place one swab in the lysis tube. (3) Vortex. (4) Squeeze drops into heat 
treatment tube. (5) Place heat treatment tube into 95oC heat block for 10 minutes. (6) 
Vortex heat-treated tube, then pipette 50 microliters of this sample to the test device 
“test” and “control” compartments. (7) Close reaction device and tap to remove all air 






OPERATOR ASSESSMENT OF ASSAY PERFORMANCE CHARACTERISTICS 
Name _______________________________________ 
 
Operator Survey of the Performance of illumigene® Group A Streptococcus DNA Amplification Assay 
Versus Routine Culture for Group A Streptococcus Pharyngitis 
 
Please rank the illumigene® Group A Streptococcus DNA Amplification Assay and  Routine Culture for 
Group A Streptococcus Pharyngitis based on your experience with both.  Rank each statement on a scale of 
1+ to 4+ as below:   
 
1+  least convenient             2+  less convenient         3+  more convenient     4+  most convenient 
 
1. The training time required for competent use of the illumigene® Group A Strep Assay is 
________.  
2. The training time required for competent use of Routine Culture for GAS is ________. 
 
3. Time required for definitive diagnosis of GAS with the illumigene® assay is ________. 
4. Time required for definitive diagnosis of GAS with Routine Culture for GAS is ________. 
 
5. Procedural complexity of the illumigene® assay is ________. 
6. Procedural complexity of Routine Culture for GAS is ________. 
 
7. Number of steps required for the illumigene® assay is ________ . 
8. The number of steps required for Routine Culture for GAS is ________. 
 
9. Hands-on time required by technologist for the illumigene® assay is ________. 
10. Hands-on time required by technologist for Routine Culture for GAS is ________. 
 
11. Ease of interpretation of illumigene® is ________. 
12. Ease of interpretation of  Routine Culture for GAS is ________. 
 
13. Need for  repeat testing on illumigene®  to obtain valid result is ________. 
14. Need for repeat testing on Routine Culture for GAS to obtain valid result is ________. 
 
15. Overall convenience of illumigene® assay is ________. 
16. Overall convenience of Routine Culture for GAS is ________. 
Figure D.1.  Operator Assessment of Assay Performance  








CENTOR SCORES FOR CLINICAL MANAGEMENT OF PHARYNGITIS 
Table E.1.  Centor Scores for Clinical Management of Pharyngitis Criteria	   Points	  Absence	  of	  cough	   1	  Tonsillar	  exudate	  or	  swelling	   1	  Swollen	  cervical	  lymph	  nodes	   1	  Temperature	  elevated	  to	  38O C 1	  Patient	  age	  3-­‐14	  years	   1	  Patient	  age	  15-­‐44	  years	   0	  Patient	  age	  greater	  than	  45	  years	   -­‐1	  
 
Used widely in Europe, Centor scores have not been as popular in the United States. 
Using the above algorithm, a child of 13 years presenting with tonsillar exudates and 
fever would have a Centor score of 3.  According to the American Society for Internal 
Medicine, Centor scores of 2–3 are recommended to have rapid antigen detection testing, 
with throat cultures reserved only for children. A Centor score of 4 warrants treatment 
without confirmatory testing, but this assessment alone results in antibiotic treatment of 
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